In the last trading session, 1.25 million Beam Therapeutics Inc (NASDAQ:BEAM) shares changed hands as the company’s beta touched 1.88. With the company’s per share price at $22.53 changed hands at -$0.25 or -1.10% during last session, the market valuation stood at $1.85B. BEAM’s last price was a discount, traded about -119.71% off its 52-week high of $49.50. The share price had its 52-week low at $16.95, which suggests the last value was 24.77% up since then. When we look at Beam Therapeutics Inc’s average trading volume, we note the 3-month average coming to 1.52 million.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Instantly BEAM was in red as seen at the end of in last trading. With action 6.17%, the performance over the past five days has been green. The drop to weekly highs of 24.60 subtracted -1.10% to the stock’s daily price. The company’s shares are showing year-to-date downside of -17.23%, with the 5-day performance at 6.17% in the green. However, in the 30-day time frame, Beam Therapeutics Inc (NASDAQ:BEAM) is -21.80% down.
Beam Therapeutics Inc (BEAM) estimates and forecasts
Data shows that the Beam Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -8.00% over the past 6 months, a -221.51% in annual growth rate that is considerably lower than the industry average of 13.10%. Year-over-year growth is forecast to reach -83.20% down from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 16.97M. 11 analysts are of the opinion that Beam Therapeutics Inc’s revenue for the current quarter will be 15.2M. The company’s revenue for the corresponding quarters a year ago was 24.21M and 20.12M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -29.90%. The estimates for the next quarter sales put growth at -24.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 5.58%. The 2024 estimates are for Beam Therapeutics Inc earnings to decrease by -177.99%, but the outlook for the next 5-year period is at -3.70% per year.
BEAM Dividends
Beam Therapeutics Inc is expected to release its next quarterly earnings report in June.
